Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic
| Autor: | Filip K. Knop, Asger Lund, Katrine B. Hansen, Henrik Vestergaard, Tina Vilsbøll, Mathilde Svendstrup |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Injections Subcutaneous Endocrinology Diabetes and Metabolism Glucagon-Like Peptides Type 2 diabetes Drug Administration Schedule Endocrinology Glucagon-Like Peptide 1 Internal medicine Diabetes mellitus Outpatients Internal Medicine medicine Humans Aged Retrospective Studies Glycated Hemoglobin business.industry Semaglutide Middle Aged medicine.disease Confidence interval Treatment Outcome Diabetes Mellitus Type 2 Quartile Cohort Female business Body mass index Cohort study |
| Zdroj: | Diabetic Medicine. 38 |
| ISSN: | 1464-5491 0742-3071 |
| DOI: | 10.1111/dme.14655 |
| Popis: | AIMS The once-weekly administered glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) semaglutide, has, in clinical trials, demonstrated significant reductions in glycated haemoglobin A1c (HbA1c ) and body weight in persons with type 2 diabetes. We evaluated the real-world clinical effects of semaglutide once weekly in a hospital-based diabetes out-patient clinic. METHODS This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naive persons (n = 37) and GLP-1RA-experienced persons (n = 82). Person characteristics at inclusion: age [median (quartiles)]: 65 (57, 72) years; body weight 99 (86, 118) kg; body mass index (BMI) 33 (29, 38) kg/m²; HbA1c 61 (54, 69) mmol/mol/(7.7 (7.1, 8.5) %). Data were collected at baseline and after 3, 6 and 12 months of semaglutide treatment. Data were analysed using a general linear mixed model for repeated measurements. RESULTS After 12 months, the reductions in HbA1c were (mean [95% confidence interval]: GLP-1RA naive: -12.8 [-17.0, -8.5] mmol/mol/ -1.2 [-1.6, -0.8]% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text